swg_trd, I think Hutschi did a fairly good job in populating the cancer diagnostic tests landscape with a minefield of initiatives ranging from old time biopsy based, over DNA to Exosomes.
Of ALL these there was NOT ONE SINGLE TEST that could do what PPHM's test can do and has been proven in a proof-of-concept clinical trial (after it was of course tested in pre-clinical setting at UTSW).
The current person in lead of THE GRAIL (an ex-CEO of a pharma company involved in the diagnostic tests) has said what we needed to know:
- DNA/RNA based tests suffer from DNA mutations and problem that he things will not, or at least not easily or soon be solved. DNA tests are not fast and cheap and in the current state are complex due to the need of a base-line per patient.
- The market is (with PPHM test that is about to become WAS) looking for the all round test. For such test, instead of an about 10BIL$ market in cancer diagnostics there is a 100-200BIL$ market.
PPHM's Exosome based blood test is FAST, SIMPLE and CHEAP. No centrifugal activity needed, no tissue needed just blood, no base-line needed per patient just take blood when needed, no need of a specialised facility for the patient to go to because every doctor/nurse can take blood, and the test comes as a simple straight forward kit allowing if wanted to obtain the results before the patient goes back home. The PREDICTOR of Oncology!
The test allows for BINARY testing (cancer vs no cancer without being cancer specific) and is therefore satisfying the first of the all round requirements that allows it to be a PRO-ACTIVE test (for instance done during your annual). That makes it IMMEDIATELY deployable as a cheap pre-selection diagnostic tool before engaging in more expensive searches (until the full featured version of the test is available to even avoid these expensive searched).
The test allows to differentiate between benign and not benign. This not only allows to ease of mind of some patients but ALSO allows for a form of triage (you'dd first treat the non-benign tumors before you remove (if you remove) the others).
The test allows to evaluate the STAGE the cancer is in. This allows for another form of triage and treat later stage patients first in a planning/schedule. But MORE IMPORTANTLY it allows to do the follow-up of treatments because the stage says something about the tumour size. So if it progresses or regresses the stage changes. That was another very important feature of this test needed to tap into that hge 100-200Mil$ market.
The test allows to distinguish between the types of solid cancers. The patent application shows a table of the ones that were already supported at the moment of the filing (the important once were in there already) and the list is being extended.
Last but not last we must mention that many tests out there have a lot of false positives/negatives. That poses a serious problem, certainly in the DAN arena where that aspect is accentuated by the mutation problem. PPHM test uses a DOUBLE mechanism. It uses PS levels (or PS-Levels in micro-vesicles) as a GENERAL YES/NO. Only THEN will more specific molecule analyses do the rest. So under an initial NO there cannot be any false positives or false negatives of the more difficult second leg. That EXCLUDES the FALSE POSITIVES 100% and leaves only room for a FALSE POSITIVE of the WRING CANCER TYPE (the proof-of-concept had I believe 1 patient were the test said that she had a cancer and no ovarian cancer was found but the woman seemed to have breast cancer - by memory).
We can therefor say that this test has 100% accuracy on the binary (cancer/no cancer) and near 100% accuracy on the type detection. But if that last one is wrong it is no big deal as the doctor will immediately see it and test for another cancer.
So PPHM, exclusively, holds the rights to the UTSW IP related to an exosome blood test that has all the above properties. It holds an 100% accuracy proof-of-concept and it is looking for a partner (I posted a list with about 50+ potential companies that are involved in diagnostics and could talk with PPHM among whom the big boys such as JNJ/Janssens Diagnostics, Roche Diagnostics, AstraZeneca Diagnostics, etc).
I hope this helps you with the Exosome test landscape.
Market Data 
Markets 
